Donanemab in Early Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease. METHODS: ), the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory (ADCS-iADL), and the Mini-Mental State Examination (MMSE), as well as the change in the amyloid and tau burden on PET. RESULTS: A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. The baseline iADRS score was 106 in both groups. The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P = 0.04). The results for most secondary outcomes showed no substantial difference. At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo. Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab. CONCLUSIONS: In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer's disease. (Funded by Eli Lilly; TRAILBLAZER-ALZ ClinicalTrials.gov number, NCT03367403.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The phase 3 trial of donanemab, monoclonal antibody that target Aβ plaques, fibrils, soluble protofibrils, and oligomeric Aβ species all targeting A β plaques, required p eople with early AD to have both positive amyloid PET and tau-PET, further dividing participants into low and intermediate/high positive tau burden groups.(464)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [464]
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“The first therapies for AD targeting the removal of amyloid are now being approved with modest positive outcomes, although associated with several side effects (Sims et al. 2023; Mintun et al. 2021; Van Dyck et al. 2023).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“One response to these problems has been the design of clinical instruments that purport to be able to reveal treatment effects with greater sensitivity: for example, the iADRS 83 or the preclinical Alzheimer cognitive composite 96 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [83]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citationMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Cited by
Items 801–900 of 1,008
Mitophagy in Alzheimer’s Disease: A Bibliometric Analysis from 2007 to 2022
Wang, H., Yan, X., Zhang, Y., Wang, P., Li, J., & Zhang, X. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230139 · Cited by 9
Aducanumab and disease modifying treatments for Alzheimer's disease
Thomas, E., Wasunna‐Smith, B., & Kuruvilla, T. (2021) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.711 · Cited by 12
Lecanamab Ushers in a New Era of Anti‐Amyloid Therapy for Alzheimer's Disease
Musiek, E. S., McDade, E., & Holtzman, D. M. (2023) · Annals of Neurology · doi:10.1002/ana.26643 · Cited by 9
“Finally, donanemab, which targets the N-terminal pyroglutamate epitope of established Aβ-plaques (not protofibrils), has recently shown robust amyloid PETlowering effects in a phase II study that was associated with a clinical benefit similar in magnitude to that seen with lecanemab.(12) Although the removal of specif…”
ResultTau Imaging with 18 F-MK6240 across the Alzheimer’s Disease spectrumPreprint
Rowe, C. C., Doré, V., Krishnadas, N., Burnham, S. C., Lamb, F., Mulligan, R. S., Bozinovski, S., Laws, S. M., Tyrrell, R., Huang, K., et al. (2022) · medRxiv · doi:10.1101/2022.02.13.22270894 · Cited by 11
Benninghoff, J., & Perneczky, R. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_195 · Cited by 8
Kang, D. W., Wang, S., Um, Y. H., Kim, S., Kim, T., Kim, D., Lee, C. U., & Lim, H. K. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1428535 · Cited by 8
“There is growing interest in monoclonal antibodies targeting A b for their potential to slow cognitive decline by 25-30% (4, 5), although their effects are less pronounced in MCI than in mild AD (6).”
Hammers, D. B., Musema, J., Eloyan, A., Thangarajah, M., Taurone, A., Joie, R. L., Touroutoglou, A., Vemuri, P., Kramer, J. H., Aisen, P., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100075 · Cited by 8
“Although recent advancements in disease-modifying treatments for LOAD are promising [ 14 , 15 ], the aforementioned results from LEADS suggest that EOAD and LOAD differ in important ways [ 13 ].”
Self-citationNeocortical tau propagation is a mediator of clinical heterogeneity in Alzheimer’s disease
Chongtham, A., Ramakrishnan, A., Farinas, M., Broekaart, D. W. M., Seo, J. H., Zhu, C. W., Sano, M., Shen, L., & Pereira, A. C. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02998-y · Cited by 13
“This study demonstrates the importance of taking tau pathology into account in clinical trials [17].”
Squitti, R., Pal, A., Ivanova, I. D., Marianetti, M., & Rongioletti, M. C. A. (2025) · Biomolecules · doi:10.3390/biom15060788 · Cited by 9
“Among the available anti-amyloid agents, Donanemab has shown the strongest clinical effect [2], while Gantenerumab, despite achieving amyloid clearance, failed to meet its primary efficacy endpoints [3].”
Bridging the Gap: The Neuro-immune Axis as a Key Player in Neurodegenerative Disorders
Liu, T., Wu, H., & Wei, J. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01439-8 · Cited by 10
“Donanemab [165], targeting pyro-glutamate Aβ, has demonstrated significant Aβ clearance and delayed clinical progression in Phase III trials.”
Multidimensional MRI reveals cortical astrogliosis linked to dementia in Alzheimer’s disease
Barsoum, S., Latimer, C. S., Nolan, A., Barrett, A., Chang, K., Troncoso, J. C., Keene, C. D., & Benjamini, D. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf245 · Cited by 13
Predicting brain amyloid load with digital and blood-based biomarkers
Chen, W., Liao, Y., Shi, X., Su, F., Kong, H., Fang, Y., Zheng, Y., Zhou, J., Liu, G., Zhou, X., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01801-y · Cited by 9
Alo, B., & Lamers, C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00153 · Cited by 11
da Silva, A. M. P., Falcão, L., Ribeiro, F. V., Menezes, I. R., Leite, M. G. H. S. J., Farias, E., Nascimento, M., Han, M. L., Telles, J. P. M., Franco, E. D. S., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251361044 · Cited by 10
“For amyloid-negative conversion (Supplemental Figure 3), omission of the Sims et al. 9 study resulted in the highest risk estimate (RR, 30.91; 95% CI, 2.02 – 474.25), whereas excluding Mintun et al. 13 yielded the lowest estimate (RR, 1.67; 95% CI, 0.27 – 10.40).”
InfluentialOverview of Proteomic Analysis of Amyloid Plaques and Neurofibrillary Tangles in Alzheimer’s Disease
Grewal, A., Raikundalia, S., Zaia, J., & Sethi, M. K. (2025) · Biomolecules · doi:10.3390/biom15091310 · Cited by 10
“…in plaques and NFTs are heavily crosslinked, rendering them resistant to proteolytic digestion and conventional PTM enrichment techniques, such as immobilized metal affinity chromatography (IMAC) for phosphopeptides and hydrophilic interaction chromatography (HILIC) for glycopeptides [16].”
InfluentialMa, M., Wang, J., Zhong, W., Li, Z., & Zhao, Y. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202517917 · Cited by 11
Abushakra, S. R., Doraiswamy, P. M., Hey, J. A., Tosun, D., Barkhof, F., Barakos, J. A., Petrella, J. R., Kesslak, J. P., Power, A., Sabbagh, M. N., et al. (2025) · CNS Drugs · doi:10.1007/s40263-025-01251-y · Cited by 16
“The 18-month antibody trials were conducted across all apolipoprotein E (APOE) genotypes [41–45], while the valiltramiprosate trial was conducted in APOE4/4 subjects [46].”
InfluentialLecanemab appropriate use recommendations for clinical practice in the UK
Mummery, C. J., Rasmussen, J., Blackburn, D. J., Coulthard, E. J., Davies, R., Dorsey, R., Fox, N. C., Hosseini, A. A., Ivenso, C., Jones, M. S., et al. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2025-336597 · Cited by 15
Defining patient‐centered amyloid PET thresholds for the onset of tauopathy in Alzheimer's disease
Zhu, Z., Steward, A., Dehsarvi, A., Roemer, S. N., Dewenter, A., Biel, D., Hirsch, F., Frontzkowski, L. K., Pescoller, J., Klonowski, M., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71064 · Cited by 8
Self-citationWasano, K., & Jørgensen, K. (2026) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2025.101792 · Cited by 9
“7 Although pharmaceutical developments, such as monoclonal antibodies aimed at removing protofibrillar forms of amyloid-beta from the brain, 8,9 show promise for reducing clinical dementia, their limited effectiveness and high costs have resulted in inconsistent approval and limited adoption in…”
Apolipoprotein E4 in Alzheimer’s Disease: Role in Pathology, Lipid Metabolism, and Drug Treatment
Al-Ghraiybah, N. F., Alkhalifa, A. E., Itokazu, Y., Farr, T., Pérez, N., Ali, H., & Kaddoumi, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27021004 · Cited by 11
“On the other hand, some therapies seem slightly more beneficial or better tolerated in ApoE4 carriers compared to non-carriers [93,94].”
Glymphatic dysfunction links vascular pathology to Alzheimer’s biomarkers and cognitive decline
Kang, S. H., Kim, S., Kim, Y. J., Yoo, H., Lee, E. H., Jang, H. J., Shin, D., Yun, J., Kim, J. P., Kim, H., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01964-2 · Cited by 11
Gnoth, K., Geißler, S., Feldhaus, J. S., Taudte, N., Ilse, V., Zürner, S., Greiser, S., Braumann, U., Rahfeld, J., Cynis, H., et al. (2022) · Biomolecules · doi:10.3390/biom12030399 · Cited by 9
“(IV) Combinational therapy allows a reduction in anti-Aβ antibody dosage, thereby preventing side effects, since monoclonal antibodies showed ARIA-H and ARIA-E in clinical trials in a dosage-dependent manner.”
BackgroundInfluentialDisease-modifying vs symptomatic treatments: Splitting over lumping
Duque, K. R., Vizcarra, J. A., Hill, E. J., & Espay, A. J. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00020-5 · Cited by 9
Zagorski, K., King, O., Hovakimyan, A., Petrushina, I., Antonyan, T., Chailyan, G., Ghazaryan, M., Hyrc, K. L., Chadarevian, J. P., Davtyan, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129797 · Cited by 9
“The most valuable evidence in favor of targeting pE3Aβ is the recent clinical trial performance of donanemab, a humanized IgG1 monoclonal antibody generated from mouse mAb, mE8-IgG2a [31,32].”
BackgroundTosun, D., Thropp, P., Southekal, S. S., Spottiswoode, B. S., Fahmi, R., & Initiative, A. D. N. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13164 · Cited by 9
“5 Researchers have also begun developing tau-targeted vaccines.”
On the Inadequacy of the Current Transgenic Animal Models of Alzheimer’s Disease: The Path Forward
Volloch, V., & Rits‐Volloch, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052981 · Cited by 9
A glycan biomarker predicts cognitive decline in amyloid- and tau-negative patients
Zhou, R. Z., Duell, F., Axenhus, M., Jönsson, L., Winblad, B. G., Tjernberg, L. O., & Schedin‐Weiss, S. (2024) · Brain Communications · doi:10.1093/braincomms/fcae371 · Cited by 8
“1,31,32 Linear mixed effects models are commonly used to estimate the effect of certain variables on disease progression and may be appropriate in some instances.”
Disease progression trajectory curves to estimate saved time in Alzheimer's disease trials
Shan, G., Zhang, Y., Tang, Z., Wang, G., & Wu, S. S. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.107814 · Cited by 8
Crowley, P., O’Donovan, M. R., Leahy, P., Flanagan, E., & Ó’Caoimh, R. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22060956 · Cited by 12
“Unfortunately, despite the recent emergence of disease-modifying therapies [27,28], there remains no curative treatment for dementia.”
Effect of Age on Clinical Trial Outcome in Participants with Probable Alzheimer’s Disease
Targum, S. D., Fosdick, L., Drake, K. E., Rosenberg, P. B., Burke, A. D., Wolk, D. A., Foote, K. D., Asaad, W. F., Sabbagh, M. N., Smith, G. S., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210530 · Cited by 9
Willis, B. A., Lowe, S. L., Monk, S. A., Cocke, P. J., Aluise, C. D., Boggs, L. N., Borders, A. R., Brier, R. A., Dean, R. A., Green, S. J., et al. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210037 · Cited by 8
“Recent results from monoclonal antibodies targeting deposited amyloid plaque has led to renewed interest in the amyloid hypothesis [35, 36], and therefore agents that target this pathology.”
BackgroundSelf-citationWang, Y.-R., Wang, M.-T., Zeng, X.-Q., Liu, Y.-H., & Wang, Y.-J. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220775 · Cited by 7
Takechi, R., Sharif, A., Brook, E., Majimbi, M., Chan, D. C., Lam, V., Watts, G. F., & Mamo, J. C. L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1127481 · Cited by 10
“Numerous studies have reported an association between cerebral Ab burden with decline in cognitive performance and memory (3, 4), so it is unsurprising that Ab is considered an important therapeutic target to treat AD (5).”
BackgroundEscolar, G., Páez, A., & Cid, J. (2022) · Plasmatology · doi:10.1177/26348535221131685 · Cited by 10
Zammit, A. R., Bennett, D. A., & Buchman, A. S. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1303912 · Cited by 11
“Indeed, even if therapies are developed for a specific pathology (Mintun et al., 2021; van Dyck et al., 2023), the beneficial effect from treating a single pathology might be minor given the large number of combinations of person-specific burden of mixed-brain pathologies observed in aging brains…”
Ray, R., Chowdhury, S. G., & Karmakar, P. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.109906 · Cited by 8
Rodríguez, A., Calero, O., Veiga, S., Menacho-Román, M., Arribas, I., Cano, L., García-Ribas, G., & Calero, M. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-025-01811-w · Cited by 8
“In addition to AD risk, APOE ε4 carriers, especially those who are APOE ε4/ε4 homozygotes, exhibit an increased susceptibility to Amyloid-Related Imaging Abnormalities (ARIA) when treated with anti-amyloid antibodies [10, 11].”
Grenon, M. B., Papavergi, M.-T., Bathini, P., Sadowski, M. J., & Lemere, C. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115754 · Cited by 7
Abu‐Rumeileh, S., Arajyan, G., Reiman, E. M., Otto, M., Weise, C. M., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14151 · Cited by 6
Lu, J., Zhou, Q., Zhu, D., Song, H., Xie, G., Zhao, X., Huang, Y., Cao, P., Wang, J., & Shen, X. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.11.010 · Cited by 8
“Alzheimer’s disease (AD) is a neurodegenerative disease with clinical hallmarks of progressive cognitive impairment and memory loss and even accompanied by personality changes and mental disorders 1,2 .”
Leveraging mHealth wearables for managing patients with Alzheimer’s disease: a scoping review
Noda, K., Kageyama, I., Kobayashi, Y., Lim, Y., Sengoku, S., & Kodama, K. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104363 · Cited by 7
Bo, M. D., Gambirasi, M., Vruzhaj, I., Cecchin, E., Pishdadian, A., Toffoli, G., & Safa, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26114982 · Cited by 10
“In AD, three anti-amyloid antibodies have received FDA approval: aducanumab (2021), lecanemab (2023), and donanemab (2024) exhibit a 23–35% reduction in clinical decline, albeit with differing risks of ARIA [65–67].”
Chen, C. D., Franklin, E. E., Li, Y., Joseph‐Mathurin, N., Burns, A., Hobbs, D. A., McCullough, A. A., Schultz, S. A., Xiong, C., Wang, G., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02890-7 · Cited by 9
“In response, many treatment strategies for AD have focused on Aβ as a drug target, spurring the development of several anti-Aβ monoclonal antibody-based therapeutics [27, 33, 37, 51, 55].”
Self-citationPanda, H. S., Dhokne, M. D., Thakur, S., Singh, N. K., Datusalia, A. K., & Panda, J. J. (2025) · Small · doi:10.1002/smll.202411701 · Cited by 7
Yu, W., Li, Y., Liu, Z., Hua, S., Tan, Z., Tang, W. X., Gao, M., Zhou, X., & Hua, Z. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102850 · Cited by 8
Yim, S., Park, S., Lim, K., Kang, H., Shin, D., Jo, H., Jang, H., Weiner, M. W., Zetterberg, H., Blennow, K., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213954 · Cited by 7
“10,11 Consequently, detecting A β accumulation in vivo become critical for identifying patients with mild cognitive impairment (MCI) or early Alzheimer-type dementia (ATD) who may bene fi t from these therapies.”
Protein quality control systems in neurodegeneration – culprits, mitigators, and solutions?
Ciechanover, A. J., & Livneh, I. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1604076 · Cited by 10
“…of the mechanisms that underlie NDD is still limited, the proteinopathic mechanism of NDDs’ pathogenesis is supported in early cases of Alzheimer’s by the effect of three monoclonal antibodies (Donanemab, Lecanemab, and Aducanumab) on the amyloid burden and clinical course of the disease (117–120).”
McDade, E., Barthélemy, N. R., Wang, G., Li, Y., Cao, Y., Gordon, B. A., Benzinger, T. L. S., Clifford, D. B., Goate, A., Renton, A. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70689 · Cited by 8
Biel, D., Steward, A., Dewenter, A., Dehsarvi, A., Zhu, Z., Roemer, S. N., Frontzkowski, L. K., Hirsch, F., Palleis, C., Höglinger, G. U., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70783 · Cited by 10
Kim, M., Kwon, H., Sohn, S., Lee, W. J., Cho, K., & Kim, G. W. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251391820 · Cited by 13
“13 These clinical advancements highlight that while reducing amyloid burden has been validated through imaging and fl uid biomarkers, translating these effects into substantial clinical bene fi ts remains challenging.”
Gallo, C., Verrillo, L., Manzo, E., Cauzzi, E., Barbera, L. L., Sabatino, G., Paolis, M. L. D., Sciacca, M. F. M., Barra, G., Peroni, E., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03634-w · Cited by 10
“Monoclonal antibodies directed against Aβ species emerged as a promising approach to reduce plaque burden and to slow cognitive decline, potentially exerting their effects, in part, through the modulation of glial dynamics [11, 12].”
Skyles, T. J., Bouchal, S. M., Giarratana, A. O., Wengler, J., Hart, I. R., Greig, E. E., Singh, H., Huang, S. S., Martinez, F., Nguyen, B. D., et al. (2026) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.125.271835 · Cited by 9
Atri, A., Apostolova, L. G., Iwata, A., Wessels, A. M., Atkins, A. S., Lu, M., Ye, W., Ryan, S., & Doty, E. G. (2026) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200621 · Cited by 9
“10,21 This report reviews the e ffi cacy of donanemab across several clinical outcome assessments and analytic approaches.”
Self-citationChandler, J., Done, N., Desai, U. S., Georgieva, M. V., Gómez-Liévano, A., Ye, W., Zhao, A., Eid, D., Hilts, A., Kirson, N. Y., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.27 · Cited by 8
“…(i.e., age, gender, race, ethnicity, education, marital status), disease characteristics (i.e., APOE ε4 genotype status), and cognitive (CDR-SB, MMSE, Alzheimer’s Disease Assessment Scale Cognitive Subscales 11 [ADAS-Cog 11] and 13 [ADAS-Cog 13]) and functional (FAQ) characteristics were evaluated.”
Conveying Risks of Harm in Alzheimer Disease by Amyloid Lowering
Thambisetty, M., & Howard, R. J. (2024) · JAMA · doi:10.1001/jama.2024.7548 · Cited by 7
P2Y1 receptor in Alzheimer’s disease
Luo, S., Wang, Y., & Hisatsune, T. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-02103 · Cited by 12
“Donanemab (Mintun et al., 2021) Early symptomatic AD Aβ Antibody targeting amyloid-beta Submitted for FDA approval, with phase 3 trials showing significant slowing of cognitive and functional decline.”
BackgroundNeve, A., Das, B., Wojtowicz, J., Huang, Z., Bullain, S., Watkin, M., Lott, D., Bittner, T., Delmar, P., Klein, G., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240221 · Cited by 8
Jayaprakash, N., & Elumalai, K. (2024) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.155 · Cited by 19
“Targeting N3pG amyloid, donanemab has demonstrated a slower cognitive decline by 32% in the TRAILBLAZER ‐ ALZ 2 study [24], with some patients showing an end to disease progression, particularly among those with light ‐ to ‐ moderate tau pathology.”
Xu, J., Liu, B., Feng, Z., Yu, X., Shang, G., Liu, Y., Sun, Y., Yang, H., Chen, Y., Zhang, Y., et al. (2024) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823241297852 · Cited by 7
“42 The MoCA is an assessment tool for rapid screening of cognitive dysfunction.”
Siemers, E., Feaster, T., Sethuraman, G., Sundell, K. L., Skljarevski, V., Cline, E. N., Zhang, H., Jerecìć, J., Honig, L. S., Salloway, S., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100005 · Cited by 8
“Studies for lecanemab, targeting A 𝛽 protofibrils, and donanemab, targeting pyroglutamylated A 𝛽 primarily localized in amyloid plaques, showed robust reduction of plaques in Phase 2 and Phase 3 studies [ 20– 23 ] with statistically significant slowing of clinical progression.”
Self-citationOh, J. M., Kim, S. H., Pandey, B. P., Shin, W., Son, H. J., Kwon, Y. J., & Kim, H. (2025) · Fitoterapia · doi:10.1016/j.fitote.2025.106484 · Cited by 7
Lozupone, M., Dibello, V., Resta, E., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Mollica, A., Berardino, G., et al. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2500752 · Cited by 9
“In early 2023, findings of the Phase II TRAILBLAZER-ALZ study in early AD patients (MCI due to AD and mild AD dementia) were promising enough to prompt a submission for accelerated approval to the U.S. FDA [57] (Table 1), without success.”
Dominantly inherited Alzheimer’s disease: a compass for drug development
Rabinovici, G. D. (2021) · Nature Medicine · doi:10.1038/s41591-021-01434-2 · Cited by 8
Krankheitsmodifizierende Therapieansätze bei Alzheimer-Krankheit
Frölich, L., & Hausner, L. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01222-w · Cited by 13
The Arabic Translation and Cross-Cultural Adaptation of the Bristol Activity of Daily Living Scale
Alkeridy, W., Khalifah, R. A., Mohammedin, A., Khallaf, R. A., Muayqil, T., & Bucks, R. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-215489 · Cited by 4
Palliative care for patients with advanced dementia
Navia, R. O., & Constantine, L. A. (2022) · Nursing · doi:10.1097/01.nurse.0000820024.83629.ee · Cited by 11
Emerging concepts towards a translational framework in Alzheimer’s disease
Cozachenco, D., Zimmer, E. R., & Lourenco, M. V. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105246 · Cited by 8
Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET
Therriault, J., Lussier, F. Z., Tissot, C., Chamoun, M., Stevenson, J., Rahmouni, N., Pallen, V., Bezgin, G., Servaes, S., Kunach, P., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12391 · Cited by 8
Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer’s disease
Shukla, A. K., & Misra, S. (2023) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2023-0176 · Cited by 10
Nilsson, B., Bylund, J., Halldin, M. M., Rother, M., Rein‐Hedin, E., Önnestam, K., & Segerdahl, M. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03645-1 · Cited by 9
“Encouraging clinical study data on the efficacy of antibodies targeting the amyloid cascade as a treatment for Alzheimer’s disease is emerging [4–6].”
BackgroundMethodDrugs for Alzheimer’s disease: Where are we coming from? Where are we going?
Angioni, D., Delrieu, J., Coley, N., Ousset, P., Shi, J., & Vellas, B. J. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.02.021 · Cited by 7
Sobral, M. V. S., Soares, V. G., Gonçalves, O. R., de Abreu, V. S., Bendaham, L. C. A. R., Batista, B. L. L., & dos Santos, M. A. R. (2024) · Archives of Gerontology and Geriatrics Plus · doi:10.1016/j.aggp.2024.100016 · Cited by 7
Feldman, H., Luchsinger, J. A., Léger, G. C., Taylor, C., Jacobs, D. M., Salmon, D. P., Edland, S. D., Messer, K. S., Revta, C., Flowers, S. A., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302998 · Cited by 7
MRI-free processing of tau PET images for early detection
Carlson, M. L., Smith, V., Johns, E., Young, C. B., Vossler, H. A., Ward, T. J., Harrison, T. M., Tosun, D., Hohman, T. J., Landau, S. M., et al. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00369 · Cited by 6
More than microglia: myeloid cells and biomarkers in neurodegeneration
Kodosaki, E., Bell, R., Sogorb‐Esteve, A., Wiltshire, K., Zetterberg, H., & Heslegrave, A. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1499458 · Cited by 6
Menéndez‐González, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212029 · Cited by 9
Yokoyama, Y., Harada, R., Kudo, K., Iwata, R., Kudo, Y., Okamura, N., & Furumoto, S. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108986 · Cited by 8
Altered Clearance and Amyloid-Related Imaging Abnormalities
Cogswell, P. M., Burkett, B. J., Johnson, D. R., & Pillai, J. J. (2025) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2024.12.002 · Cited by 7
Marra, C., Beccia, F., Caffarra, P., L’Abbate, F., Agosta, F., Benussi, A., Bonanni, L., Bruni, A. C., Bruno, G., Cappa, S. F., et al. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08143-5 · Cited by 7
Cohen, A. D., & Villemagne, V. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70291 · Cited by 7
Sadruddin, Z., Harris, K., Bilsborough, E., Sciba, L., Vargas, A. F., Shyer, M. N., Hinojosa, M., Colby, J., Chung, K., Farrell, C. M., et al. (2025) · Geriatric Nursing · doi:10.1016/j.gerinurse.2025.05.010 · Cited by 8
The parasagittal dural space of the human brain
Donahue, M. J., McKnight, C. D., Claassen, D. O., & Hett, K. (2025) · Brain · doi:10.1093/brain/awaf204 · Cited by 10
“Additionally, pharmacological studies whereby cerebral peptide retention is reduced following, for example, anti-amyloid therapies, 38,72 are allowing for an understanding of how the neurofluid circuit adjusts before and after pathological peptide retention, which could provide additional…”
Liao, F., Calvo-Rodríguez, M., Chhaya, M., Sefrin, J. P., Charych, E. I., Mezler, M., Clausznitzer, D., McGlame, E. J., Zhao, K., Rodgers, A., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02892-5 · Cited by 7
“Thus, Aβ pE3 antibodies can remove most of the plaques, as measured using amyloid PET imaging, from AD brain within about 12 months [20, 27].”
Management of Alzheimer's Disease With Nanotechnological Interventions and Novel Therapeutics
Shahrukh, M., Ahmad, S., Zaafar, M., Hasan, N., & Ahmad, F. J. (2025) · Drug Development Research · doi:10.1002/ddr.70120 · Cited by 9
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
McCullough, A. A., Chen, C. D., Gordon, B. A., Joseph‐Mathurin, N., Jack, C. R., Koeppe, R., Hornbeck, R. C., Koudelis, D., McKay, N. S., Hobbs, D. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70347 · Cited by 9
“15,16 20 Dominantly inherited Alzheimer’s disease (DIAD) is a rare form of AD caused by mutations in either the presenilin-1 ( PSEN1 ), presenilin-2 ( PSEN2 ), or amyloid precursor protein ( APP ) genes.”
Self-citationPetrella, J. R., Liu, A., Wang, L., & Doraiswamy, P. M. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8946 · Cited by 6
Benetik, S. F., Proj, M., Knez, D., Košak, U., Meden, A., Krajšek, K., Pišlar, A. H., Horvat, S., Švajger, U., Tešić, N., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00933 · Cited by 6
Murakami, K., Nguyen, T. H. V., Nagao, C., Mizuguchi, K., & Bitan, G. (2025) · JACS Au · doi:10.1021/jacsau.5c00269 · Cited by 6
“31 The remaining drugs alleviate symptoms moderately and temporarily.”
Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease
Mullins, G. R., Ardayfio, P. A., Gueorguieva, I., Anglin, G., Bailey, J. A., Chua, L., Zimmer, J. A., Evans, C. D., Nery, E. S. M., Wang, H., et al. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70149 · Cited by 6
Self-citationChen, J.-D., Chen, S., Liao, C.-C., Fang, C.-Y., & Yen, G. (2025) · Food & Function · doi:10.1039/d5fo03048j · Cited by 9
Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations
Jeon, S. Y., Byun, M. S., Choi, H. J., Kim, Y. H., Gwag, C. H., Oh, Y., Park, J. E., Yi, D., Jung, G., Ahn, H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70875 · Cited by 6
Wu, J., Geng, C., Liu, L., & Tang, Y. (2025) · Medicine Plus · doi:10.1016/j.medp.2025.100112 · Cited by 9
Mangalagiu, A. G., Petrescu, B. M., Riga, S., & Vasiliu, O. (2025) · NeuroSci · doi:10.3390/neurosci7010002 · Cited by 7
“…(lecanemab, donanemab, aducanumab) Amyloid-β clearance, disease-modifying intent Lecanemab (CLARITY-AD) [38]; Donanemab (TRAILBLAZER-ALZ 2and4)[39,43]; Aducanumab EMERGE/ENGAGE, discordant, withdrawn[40] ~27–35% relative slowing of decline but small absolute CDR-SB differences; ARIA in a…”
InfluentialClinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease
Bacci, J. R., Karagianni, S., Alexopoulou, Z.-S., Moukaled, S., Tato-Fernández, C., Arunachalam, P., Aslanyan, A., Aye, S., Rocha, A. S. L., Crugel, M., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01921-5 · Cited by 12
“…are included solely for illustrative purposes and were not subjected to any additional analysis within this work Quantitative scales such as the Centiloid (CL) [123– 125] standardize Aβ-PET measures across tracers and centers [126–128], with thresholds of 24–30 CL indicating Aβ-positivity [129].”
FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?
Higgins, M. J., Wasef, V., & Kwakowsky, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020883 · Cited by 8
“…in the TRAILBLAZER-ALZ study involved 131 participants receiving donanemab 700 mg IV every 4 weeks for 3 doses, then 1400 mg IV every 4 weeks until week 72, and 126 receiving placebo IV every 4 weeks for up to 72 weeks, and 15 receiving donanemab in combination with LY3202626 (donanemab-C) [44].”
Butyrylcholinesterase signal sequence self-aggregates and enhances amyloid fibril formation in vitro
Jasiecki, J., Targońska, M., Janaszak‐Jasiecka, A., Kalinowski, L., Waleron, K., & Wasąg, B. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110783 · Cited by 8
Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics
Osaka, H., Nishida, K., & Kanazawa, T. (2024) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.185 · Cited by 12
Vascular Heparan Sulfate and Amyloid-β in Alzheimer’s Disease Patients
McMillan, I. O., Gearing, M., & Wang, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073964 · Cited by 7
Clinical predictors of Alzheimer's disease‐like brain atrophy in individuals with memory complaints
Karakaşlı, A. A., Ozkan, E., Doğan, M. K., Çap, D., Karaosmanoglu, A. A., Karahan, S., Zorlu, N., Saka, E., & Ayhan, Y. (2024) · Brain and Behavior · doi:10.1002/brb3.3506 · Cited by 5
“Disease-modifying treatment options for AD areimminentthus it is necessary to develop effective methods for early detection of AD (Mintun et al., 2021; Sims et al., 2023; Swanson et al., 2021; Van Dyck et al., 2023).”
Metadata
- Authors
- Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., Apostolova, L. G., Salloway, S. P., & Skovronsky, D. M.
- Affiliations
- Eli Lilly (United States) (US)
- From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) — both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).
- Brown University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1691-1704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3137826907
- Cited by
- 1,728
- References
- 39
- Citations by year
- 2026: 302 · 2025: 409 · 2024: 369 · 2023: 271 · 2022: 263 · 2021: 112
- FWCI
- 160.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- donanemab, early Alzheimer's disease, amyloid-beta, anti-amyloid antibodies, amyloid plaques, tau burden, activities of daily living, cognitive decline
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Alzheimer Disease, Epitopes, Brain Edema, Cognition, Double-Blind Method, Female, Humans, Male, Pyrrolidonecarboxylic Acid, Severity of Illness Index, Disease Progression, Plaque, Amyloid, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.